Xenon Pharmaceuticals (XENE) voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects. The biotech stock crashed to a six-month low. The drug at the center of the debacle is azetukalner, which Xenon is hoping will soon gain approval to treat epilepsy.
Xenon stock shot 50% higher on March 9 following positive results for azetukalner…
Extract — continue reading at the source.
Related stories
Netflix is too focused on podcasts and not enough on good shows, analysts say
Micron Just Built One Memory Stick That Replaces Four. Is MU Stock a Buy?
Global AI Infrastructure Spending Will Hit $31.6 Trillion by 2050. This Is the Stock That Could Benefit the Most
These fast-growing ETFs aim for yields as high as 17.5%. But here’s the catch.
The Oil Fund Beating USO by Harvesting Roll Yield Faces Its Biggest Test Yet
Insider Buy: Planet Fitness Director Acquires Shares Valued at Nearly $120,000